These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15330733)

  • 21. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia.
    Kyprianou N; Litvak JP; Borkowski A; Alexander R; Jacobs SC
    J Urol; 1998 Jun; 159(6):1810-5. PubMed ID: 9598465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxazosin: a new approach to hypertension and benign prostatic hyperplasia.
    Pool JL
    Br J Clin Pract; 1996; 50(3):154-63. PubMed ID: 8733335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Doxazosin for benign prostatic hyperplasia in primary care.
    Guthrie R
    Clin Ther; 1997; 19(6):1269-77; discussion 1253-4. PubMed ID: 9444439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.
    Kirby RS
    BJU Int; 2003 Jan; 91(1):41-4. PubMed ID: 12614248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
    Liu Q; Zhu Y; Liu J; Qi J; Kang J
    Int Urol Nephrol; 2017 Mar; 49(3):399-404. PubMed ID: 27987130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical therapy for benign prostatic hyperplasia: a review of the literature.
    Clifford GM; Farmer RD
    Eur Urol; 2000 Jul; 38(1):2-19. PubMed ID: 10859436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Doxazosin in the treatment of benign prostatic hypertrophy: an update.
    Wilt TJ; MacDonald R
    Clin Interv Aging; 2006; 1(4):389-401. PubMed ID: 18046916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
    Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW
    J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Benign prostatic syndrome. 3-step plan for the treatment].
    MMW Fortschr Med; 2003 Sep; 145(39):52. PubMed ID: 14649077
    [No Abstract]   [Full Text] [Related]  

  • 30. How many drugs for LUTS due to BPH are too many?
    Andersson KE
    J Urol; 2008 Sep; 180(3):811-2. PubMed ID: 18635235
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and safety of the doxazosin gastrointestinal therapeutic system for the treatment of benign prostate hyperplasia.
    Sun GH; Tsui KH; Wu TT; Chang CH; Cheng CL; Schou M
    Kaohsiung J Med Sci; 2010 Oct; 26(10):532-9. PubMed ID: 20950778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia.
    Kaplan SA; Meade-D'Alisera P; Quiñones S; Soldo KA
    Urology; 1995 Oct; 46(4):512-7. PubMed ID: 7571220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
    Chapple CR
    Eur Urol; 1996; 29(2):129-44. PubMed ID: 8647139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    MacDonald R; Wilt TJ; Howe RW
    BJU Int; 2004 Dec; 94(9):1263-70. PubMed ID: 15610102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
    Chung BH; Hong SJ; Lee MS
    Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparison of different drugs on the treatment of benign prostate hyperplasia].
    Li NC; Wu SL; Jin J; Qiu SP; Kong CZ; Song YS; Ye ZQ; Sun G; Sun YH; Sun YC; Wang XF; Na YQ
    Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(14):947-50. PubMed ID: 17961376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlled-release doxazosin in the treatment of benign prostatic hyperplasia.
    Hernandez C; Duran R; Jara J; Castaño I; Moralejo M
    Prostate Cancer Prostatic Dis; 2005; 8(4):375-80. PubMed ID: 16264771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of the alpha1-adrenergic antagonist, doxazosin, on noradrenaline-induced modulation of cytoskeletal proteins in cultured hyperplastic prostatic stromal cells.
    Smith P; Rhodes NP; Ke Y; Foster CS
    Prostate; 1999 Feb; 38(3):216-27. PubMed ID: 10068346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    Tahmatzopoulos A; Kyprianou N
    Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.
    Cooper KL; McKiernan JM; Kaplan SA
    Drugs; 1999 Jan; 57(1):9-17. PubMed ID: 9951948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.